secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-05-26T20:42:33+00:00
Accession:  0001104659-26-066317
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine prices $125M public offering of shares and warrants
-------------------------------------------------------------------

- Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.
- Warrants exercisable at $3.50/share, expire upon EDIT-401 Phase 1 data milestone or within 3 years.
- If all warrants exercised, additional proceeds ~$194.4M; net proceeds estimated ~$117M.
- Cash runway extended into second half of 2028 based on current plans.
- Underwriters: Cantor Fitzgerald and Wells Fargo; closing expected May 27, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/0001104659-26-066317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer